> **来源：[研报客](https://pc.yanbaoke.cn)** # ClearOne, Inc. Registration Statement Summary ## Core Content This document is an **amendment to a registration statement** for a public offering by ClearOne, Inc. It outlines the details of the offering, the structure of the securities being sold, and the associated risks and disclosures. The offering is for **units** consisting of **one share of Common Stock** and **one Warrant** to purchase one share of Common Stock. The offering is conducted on a **best-efforts basis**, with a **minimum of 2,857,143 units** and a **maximum of 4,285,714 units** at a price of **\$3.50 per unit**. The offering is expected to be completed in a **single closing**, with **proceeds ranging from \$10,000,000 to \$15,000,000**. The **Placement Agent** is **ThinkEquity LLC**, and it will receive **6% of the gross proceeds** as fees, with additional compensation outlined in the **Plan of Distribution**. The **Common Stock** is listed on **Nasdaq** under the symbol **“CLRO”**, and the **Warrants** will have an **exercise price of \$10.00 per share** and will **expire six months from issuance**. The Warrants will **not be listed** on any exchange, and there is **no established trading market** for them. ## Main Points - **Offering Details**: - Units consist of one share of Common Stock and one Warrant. - Minimum Offering: 2,857,143 units. - Maximum Offering: 4,285,714 units. - Price per Unit: \$3.50. - Proceeds (before expenses): \$3.29 per unit. - Placement Agent fees: \$0.21 per unit. - Total minimum proceeds: \$9,400,000. - Total maximum proceeds: \$14,100,000. - **Stockholder Approval**: - The offering involves the issuance of 20% or more of the Company's outstanding Common Stock or voting power. - Stockholder approval was obtained on **August 25, 2026** for compliance with **Nasdaq Listing Rule 5635(d)**. - **Securities Act Compliance**: - The offering is subject to **Rule 415** of the **Securities Act**, allowing for the **continuous offering** of the shares underlying the Warrants. - **Resale Prospectus**: - A **Resale Prospectus** is also included for the potential resale of up to **2,496,162 shares** of Common Stock. - The Resale Prospectus is **substantively identical** to the Primary Offering Prospectus, with the following differences: - Different **front and back covers**. - Different **“Offering”** and **“Use of Proceeds”** sections. - The **“Risks Related to this Offering”** section is deleted. - The **“Capitalization”, “Dilution”, “Description of the Securities We are Offering”** and **“Legal Matters”** sections are deleted. - A **“Selling Stockholders”** section is included. - Different **“Plan of Distribution”** sections. - **Company Overview**: - ClearOne, Inc. was incorporated in **Utah in 1983**, **reincorporated in Delaware in 2018**, and **reincorporated in Nevada in 2026**. - The company previously provided **conferencing, collaboration, and AV streaming solutions** but no longer manufactures or sells products after the **2025 disposition** of its assets to **Biamp Systems, LLC**. - Current operations include **warranty and technical support**, **public company compliance**, **collecting accounts receivable**, and **evaluating strategic alternatives**. - **The Merger**: - On **July 1, 2026**, ClearOne entered into a **Merger Agreement** with **Vivani Medical, Inc.** and its subsidiary **Cortigent**. - The **Merger** involves **Merger Sub merging with Cortigent**, with Cortigent surviving as a subsidiary of ClearOne. - The completion of the Merger is subject to **customary closing conditions** and **the Financing**. - **Cortigent Overview**: - Cortigent is a **pioneer in precision neurostimulation systems**. - Its **technology** combines **advanced neuroscience** with **proprietary microelectronics, software, and data processing**. - Cortigent has developed **artificial vision systems** such as the **Argus II** and **Orion**. - The **Argus II** was approved by the **FDA** under an **HDE** in **2013** and is used for **profound blindness due to retinitis pigmentosa**. - The **Orion** is designed to provide **artificial vision** to patients with **bilateral blindness** and is **being tested** for **stroke-related motor skill recovery**. - **Artificial Vision Systems**: - **Argus II**: Retinal implant, approved in **2013** for **profound blindness**. - **Orion**: Visual cortical implant, designed to **bypass the visual pathway** and **transmit electrical signals** to the **visual cortex**. - Both systems provide **perceptions of light and shapes**, not **normal vision**. - The **Orion** system is **under development** and **requires cranial surgery** but **does not penetrate brain tissue**. - **Risks**: - The offering involves **high risk** and is **highly speculative**. - Key risks include **business and economic uncertainties**, **capital requirements**, **dependence on key personnel**, **litigation**, **competition**, **regulatory challenges**, and **market demand**. - Cortigent faces risks related to **developing and commercializing Orion**, **obtaining FDA approval**, **market competition**, **customer relations**, **intellectual property**, and **growth management**. - **Forward-Looking Statements**: - The document contains **forward-looking statements** about future business operations, financial performance, and strategic goals. - These statements are **subject to risks and uncertainties** and are based on **management's assumptions** and **current expectations**. - The **Company does not guarantee** future results and **undertakes no obligation** to update forward-looking statements. - **Disclaimer**: - The **Securities and Exchange Commission** and **state securities commissions** have **not approved or disapproved** the securities. - The **Company and Placement Agent** have **not authorized** any other information to be provided. - The **information in this prospectus** is **accurate only as of its date** and may be **outdated** by the time of reading. ## Key Information - **Public Offering Price**: \$3.50 per Unit. - **Warrant Exercise Price**: \$10.00 per share. - **Warrant Expiration**: 6 months from issuance. - **Stockholder Approval**: Obtained on August 25, 2026. - **Merger Date**: July 1, 2026. - **Common Stock Trading Symbol**: CLRO (Nasdaq). - **Closing Price on September 3, 2026**: \$5.13 per share. - **Minimum Proceeds**: \$10,000,000. - **Maximum Proceeds**: \$15,000,000. - **Placement Agent**: ThinkEquity LLC. - **Cortigent’s Technology**: Proprietary microelectronics and data processing for **neurostimulation**. - **Potential Applications**: - **Artificial Vision** (Argus II, Orion). - **Motor Skill Recovery after Stroke** (stimulating the motor cortex). - **Cortigent’s Current Revenue**: No net income from the Argus II product. - **Regulatory Status**: Cortigent is seeking **FDA approval** for Orion. ## Summary Table | Item | Description | |------|-------------| | **Company Name** | ClearOne, Inc. | | **Jurisdiction of Incorporation** | Nevada | | **I.R.S. EIN** | 87-0398877 | | **Principal Executive Offices** | 7533 S Center View Ct. # 5311, West Jordan, Utah 84084 | | **Placement Agent** | ThinkEquity LLC | | **Public Offering Price** | \$3.50 per Unit | | **Minimum Offering** | 2,857,143 Units | | **Maximum Offering** | 4,285,714 Units | | **Warrant Exercise Price** | \$10.00 per share | | **Warrant Expiration** | 6 months from issuance | | **Stockholder Approval** | August 25, 2026 | | **Common Stock Trading Symbol** | CLRO (Nasdaq) | | **Closing Price on September 3, 2026** | \$5.13 per share | | **Minimum Proceeds** | \$10,000,000 | | **Maximum Proceeds** | \$15,000,000 | | **Cortigent’s Key Product** | Argus II (retinal implant), Orion (visual cortical implant) | | **Potential Applications** | Artificial vision, motor skill recovery after stroke | | **Regulatory Approval** | FDA approval for Argus II in 2013, pending for Orion | | **Market Opportunity** | Limited to RP for Argus II, broader for Orion | | **Company Status** | Smaller reporting company under the Exchange Act |